← ICU MEDICAL INC/DE
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $379.4m | $1.3b | $1.4b | $1.3b | $1.3b | $1.3b | $2.3b | $2.3b | $2.4b | $2.2b | |
| Cost of Revenue | $178.0m | $866.5m | $830.0m | $794.3m | $809.5m | $824.8m | $1.6b | $1.5b | $1.6b | $1.4b | |
| Gross Profit | $201.4m | $426.1m | $570.0m | $471.9m | $461.5m | $491.5m | $697.8m | $739.9m | $824.8m | $822.0m | |
| Operating Expenses | $118.5m | $441.2m | $548.4m | $364.5m | $363.3m | $368.2m | $740.7m | $717.0m | $781.8m | $779.2m | |
| Operating Income (Loss) | $82.9m | ($15.1m) | $21.6m | $107.4m | $98.2m | $123.2m | ($42.9m) | $22.8m | $43.0m | $42.8m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $2.8m | $15.0m | $16.6m | $17.7m | $23.2m | $23.8m | $139.4m | $132.1m | $134.3m | $131.4m | |
| Foreign Currency Transaction Gain (Loss), Realized | $300k | ($1.8m) | ($7.9m) | $700k | ($7.2m) | ($1.0m) | ($5.8m) | ($5.9m) | ($9.8m) | $3.8m | |
| Goodwill, Impairment Loss | $0 | — | — | — | — | — | — | — | — | — | |
| Income (Loss) Attributable to Parent, before Tax | — | — | — | — | — | $123.2m | ($114.4m) | ($78.3m) | ($66.0m) | $4.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $80.7m | $59.9m | ($8.6m) | $32.8m | $41.2m | $81.5m | ($135.6m) | ($137.0m) | ($116.0m) | ($31.5m) | |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | — | — | $0 | $0 | ($1.2m) | |
| Interest Income, Other | — | — | — | — | — | — | $4.4m | $7.5m | $10.8m | $10.3m | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $85.2m | $51.3m | $22.4m | $114.7m | $97.5m | — | — | $78.3m | $66.0m | $4.4m | |
| Net Income (Loss) Attributable to Parent | $63.1m | $68.6m | $28.8m | $101.0m | $86.9m | $103.1m | ($74.3m) | ($29.7m) | ($117.7m) | $732k | |
| Earnings Per Share, Basic | $3.90 | $3.50 | $1.41 | $4.90 | $4.16 | $4.86 | ($3.11) | ($1.23) | ($4.83) | $0.03 | |
| Earnings Per Share, Diluted | $3.66 | $3.29 | $1.33 | $4.69 | $4.02 | $4.74 | ($3.11) | ($1.23) | ($4.83) | $0.03 | |
| Weighted Average Number of Shares Outstanding, Basic | 16.2m | 19.6m | 20.4m | 20.6m | 20.9m | 21.2m | 23.9m | 24.1m | 24.4m | 24.6m | |
| Weighted Average Number of Shares Outstanding, Diluted | 17.3m | 20.9m | 21.6m | 21.5m | 21.6m | 21.8m | 23.9m | 24.1m | 24.4m | 24.9m | |
| Research and Development Expense | $13.0m | $51.3m | $52.9m | $48.6m | $42.9m | $47.5m | $93.0m | $85.3m | $88.6m | $87.5m | |
| Selling, General and Administrative Expense | $89.4m | $304.0m | $328.1m | $277.0m | $284.0m | $302.6m | $608.3m | $606.7m | $638.8m | $625.2m | |
| Current Income Tax Expense (Benefit) | $24.6m | $8.2m | $11.5m | $17.4m | $15.7m | $31.3m | $20.9m | $22.8m | $46.0m | $16.2m | |
| Interest Expense | — | $2.0m | $709k | $549k | $1.8m | $858k | $70.8m | $102.7m | $106.5m | $93.3m | |
| Interest Expense, Debt | — | — | — | — | — | — | $75.0m | $133.9m | $133.3m | $104.1m | |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | — | — | — | $19.6m | $30.0m | |
| Restructuring Costs | $774k | $18.8m | $4.5m | $8.4m | $7.9m | $140k | $9.7m | $6.7m | $19.6m | $30.0m | |
| Income Tax Expense (Benefit) | $22.1m | ($17.4m) | ($6.4m) | $13.7m | $10.6m | $20.1m | ($40.1m) | ($48.6m) | $51.7m | $2.4m | |
| Interest Income (Expense), Net | — | — | — | — | — | — | ($66.4m) | ($95.2m) | ($95.8m) | ($83.0m) | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | ($66.4m) | ($95.2m) | ($95.8m) | ($83.0m) | |
| Other Operating Income (Expense), Net | $82.9m | $15.1m | $21.6m | $107.4m | $98.2m | $123.2m | ($5.1m) | ($5.9m) | ($13.2m) | ($232k) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.